Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Cited by
Items 701–800 of 1,003
Liu, Z., Sanders, A. J., Liang, G., Song, E., Jiang, W. G., & Gong, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0576 · Cited by 24
Total Synthesis of Trapoxin A, a Fungal HDAC Inhibitor from Helicoma ambiens
Servatius, P., & Kazmaier, U. (2018) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.8b01569 · Cited by 28
Advances in the Design and Development of PROTAC-mediated HDAC Degradation
Rodrigues, D. A., Roe, A. J., Griffith, D. M., & Chonghaile, T. N. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211015092047 · Cited by 28
In vitro Model Systems for Studies Into Retinal Neuroprotection
Zhu, Y., Cao, B., Tolone, A., Yan, J., Christensen, G., Arango‐González, B., Ueffing, M., & Paquet‐Durand, F. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.938089 · Cited by 29
“Given the pleiotropic effects of HDAC activity, HDAC inhibitors, such as trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), or valproic acid (VPA), often target multiple HDACs, and the biological consequences are often unpredictable and underappreciated (Witt et al., 2009; Falkenberg and Johnstone, 2014).”
BackgroundPreclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research
Ahmed, M., Semreen, A. M., El‐Huneidi, W., Bustanji, Y. K., Abu‐Gharbieh, E., Alqudah, M. A. Y., Alhusban, A., Shara, M., Abuhelwa, A. Y., Soares, N. C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010348 · Cited by 27
“Such atypical levels can be precipitated through histone deacetylases (HDAC), which, in contrast to HMEs, deregulate the epigenetic mechanisms and as a result, cause malignancies such as GB.”
BackgroundKarati, D., Mukherjee, S., & Roy, S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02303-x · Cited by 27
Epigenetic targets in cancer and aging: dietary and therapeutic interventions
Khan, S. U., Shukla, S., Sinha, S., & Meeran, S. M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1132702 · Cited by 27
Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer
Chen, D., Shen, A., Fang, G., Liu, H., Zhang, M., Tang, S., Xiong, B., Ma, L., Geng, M., & Shen, J. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.11.002 · Cited by 25
Epigenetics and innate immunity: the ‘unTolld’ story
Hennessy, C., & McKernan, D. P. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.24 · Cited by 28
Effect of small molecules on cell reprogramming
Baranek, M., Belter, A., Naskręt-Barciszewska, M. Z., Stobiecki, M., Markiewicz, W. T., & Barciszewski, J. (2016) · Molecular BioSystems · doi:10.1039/c6mb00595k · Cited by 26
Chao, S.-W., Chen, L., Yu, C.-C., Liu, C., Lin, T. E., Guh, J., Wang, C.-Y., Chen, C.-Y., Hsu, K., & Huang, W. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.092 · Cited by 25
Shen, L., Jin, X., Wang, X., Tou, L., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000745 · Cited by 27
“In addition to genetic alterations, epigenetic processes including histone modifications are involved in the development of tumor drug resistance.([100,101]) HDACs, accompanied by histone acetyltransferases (HATs), are correlated to chromatin remodeling and transcription regulation by changing the status of histone ac…”
BackgroundThe discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay
Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1437156 · Cited by 24
“(3) Due to the substitution of 2-methylallyl-oxyl group at the ortho-position, the core scaffold of compound 2–3, i.”
BackgroundTrifluoromethyloxadiazoles: inhibitors of histone deacetylases for control of Asian soybean rust
Winter, C., Fehr, M., Craig, I. R., Grammenos, W., Wiebe, C., Terteryan‐Seiser, V., Rudolf, G. C., Mentzel, T., & Palomar, M. A. Q. (2020) · Pest Management Science · doi:10.1002/ps.5874 · Cited by 25
Recent advances in dual PROTACs degrader strategies for disease treatment
Liu, J., Liu, Y., Tang, J., Gong, Q., Yan, G., Fan, H., Zhang, X., & Pu, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116901 · Cited by 25
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups
Pires, G. S., Tolomeu, H. V., Rodrigues, D. A., Lima, L. M., Fraga, C. A. M., & Pinheiro, P. D. S. M. (2025) · Pharmaceuticals · doi:10.3390/ph18040577 · Cited by 32
“Thus, epigenetic modulation by inhibiting HDACs results in the arrest of these processes, culminating in apoptosis, and is of interest for cancer treatment [21,51,55,56].”
Pharmacology of heart failure: From basic science to novel therapies
Lother, A., & Hein, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.004 · Cited by 25
Sirtuins as Modifiers of Huntington's Disease (HD) Pathology
Neo, S. H., & Tang, B. L. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.013 · Cited by 25
HDAC inhibitors: a 2013–2017 patent survey
Freitas, M., Cuendet, M., & Bertrand, P. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1459568 · Cited by 24
“The overexpression of HDACs induces a low histone acetylation level leading to the silencing of regulatory genes and in turn to human diseases such as HIV [2] and cancer [3], as well as neurodegenerative, immune [3], and cardiac [4] disorders.”
BackgroundDavidson, J. W., Molitor, E. A., Moores, S., Gale, S. E., Subramanian, K., Jiang, X., Sidhu, R., Kell, P. J., Zhang, J., Fujiwara, H., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.04.011 · Cited by 28
Quan, M., Chen, Z., Jiao, F., Xiao, X., Xia, Q., Chen, J., Chao, Q., Li, Y., Gao, Y., Yang, H., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1489-0 · Cited by 27
Vorinostat in the acute neuroinflammatory form of X‐linked adrenoleukodystrophy
Zierfuss, B., Weinhofer, I., Kühl, J., Köhler, W., Bley, A. E., Zauner, K., Binder, J., Martinović, K., Seiser, C., Hertzberg, C., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51015 · Cited by 27
“Due to lower cytotoxicity with maintained anti-inflammatory and neuroprotective effects, some of these compounds might be more suitable for CALD treatment than Vorinostat.47 In particular, monocyte/macrophage-selective HDAC inhibitors sparing major side effects like thrombocytopenia are highly attractive candidates fo…”
BackgroundInfluentialDevelopment of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
Cao, J., Zhao, W., Zhao, C., Liu, Q., Li, S., Zhang, G., Chou, C. J., & Zhang, Y. (2020) · Molecules · doi:10.3390/molecules25214991 · Cited by 25
Moscatilin Suppresses the Breast Cancer Both In Vitro and In Vivo by Inhibiting HDAC3
Su, W., Zeng, L., & Chen, W. (2021) · Dose-Response · doi:10.1177/15593258211001251 · Cited by 24
“HDAC3 is aberrantly recruited by oncogenic fusion proteins (AML1-ETO and PML-RAR), which act as the genetic drivers of hematologic malignancies, and result in the induction of acute myeloid leukemia.(26) Moreover, Barberio et al reported that HDAC inhibitor (vorinostat) enhances in vivo immune response to PD-1/ CTLA-4…”
BackgroundHistone deacetylases: A novel class of therapeutic targets for pancreatic cancer
Xiang, X.-S., Li, P., Wang, W., & Liu, L. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188676 · Cited by 25
Bi, J., Zhang, Y., Malmrose, P. K., Losh, H. A., Newtson, A. M., Devor, E. J., Thiel, K. W., & Leslie, K. K. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04508-2 · Cited by 24
“Histone deacetylases (HDACs) are a class of enzymes that epigenetically regulate many biological processes by deacetylating histones and other regulatory proteins [12].”
BackgroundHistone deacetylase (HDACs) inhibitors: Clinical applications
Shanmukha, K. D., Paluvai, H., Lomada, S. K., Gokara, M., & Kalangi, S. K. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.02.011 · Cited by 29
A di-acetyl-decorated chromatin signature couples liquid condensation to suppress DNA end synapsis
Bao, K., Ma, Y., Li, Y., Shen, X., Zhao, J., Tian, S., Zhang, C., Liang, C., Zhao, Z., Yang, Y., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.02.002 · Cited by 28
Makki, M. S., & Haqqi, T. M. (2016) · Connective Tissue Research · doi:10.1080/03008207.2016.1211113 · Cited by 25
Shen, Y., Kim, A. L., Du, R., & Liu, L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163054 · Cited by 24
Huang, W., Ren, C., Huang, G., Liu, J., Liu, W., Wang, L., Zhu, B., Feng, X., Shi, J., Li, J., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.5469 · Cited by 24
Highly fluorescent and HDAC6 selective scriptaid analogues
Fleming, C. L., Natoli, A. L., Schreuders, J., Devlin, M. G., Yoganantharajah, P., Gibert, Y., Leslie, K. G., New, E. J., Ashton, T. D., & Pfeffer, F. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.020 · Cited by 24
Viviani, L. G., Piccirillo, E., Ulrich, H., & do Amaral, A. T. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00884 · Cited by 25
Current discovery strategies for hepatocellular carcinoma therapeutics
Dai, Q., Zhang, C., Yuan, Z., Sun, Q., & Jiang, Y. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1696769 · Cited by 26
“according to their structure [126,127]: Short-chain fatty acids”
BackgroundSirous, H., Campiani, G., Brogi, S., Calderone, V., & Chemi, G. (2020) · Molecules · doi:10.3390/molecules25081952 · Cited by 26
Structure of a SIN3–HDAC complex from budding yeast
Guo, Z., Chen, C., Lu, Y., Zhang, X., Xiao, Y., Wu, M., Gao, S., Wong, C. C. L., Zhan, X., & Wang, C. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-00975-z · Cited by 22
Hydrazides as Inhibitors of Histone Deacetylases
Carreiras, M. C., & Marco, J. L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00541 · Cited by 26
Li, L., Mei, T., & Zeng, Y. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.030 · Cited by 23
Russo, R., Cimmino, F., Pezone, L., Manna, F., Avitabile, M., Langella, C., Köster, J., Casale, F., Raia, M., Viola, G., et al. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx077 · Cited by 26
Zhou, R., Fang, S., Zhang, M., Zhang, Q., Hu, J. P., Wang, M., Wang, C., Zhu, J., Shen, A., Chen, X., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.052 · Cited by 23
Zhang, J., Duan, H., Feng, Z., Han, X., & Gu, C. (2020) · Oncogenesis · doi:10.1038/s41389-020-0230-3 · Cited by 24
RetractedPhospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
Kang, D. W., Hwang, W. C., Noh, Y. N., Kang, Y., Jang, Y., Kim, J., & Min, D. S. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29882 · Cited by 23
“…could potentially be reversed by histone deacetylase (HDAC) inhibitor, which is known as effective therapeutic anticancer agents (Esteller, 2008; Falkenberg & Johnstone, 2014; - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -…”
Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors
Dong, Y., Hu, H., Sun, Y., Qin, M., Gong, P., Hou, Y., & Zhao, Y. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127610 · Cited by 22
Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy
Gkotzamanidou, M. A., Terpou, E., Kentepozidis, N. K., & Terpos, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910406 · Cited by 25
Chang, T., Lian, Z., Ma, S., Liang, Z., Ma, X., Wen, X., Wang, Y., & Liu, R. (2022) · The Prostate · doi:10.1002/pros.24479 · Cited by 25
Zhu, H., Zhu, W., Liu, Y., Gao, T. X., Zhu, J., Tan, Y., Hu, H., Liang, W., Zhao, L., Chen, J., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115529 · Cited by 24
Targeting Triple-Negative Breast Cancer by the Phytopolyphenol Carnosol: ROS-Dependent Mechanisms
Alsamri, H., Dhaheri, Y. A., & Iratni, R. (2023) · Antioxidants · doi:10.3390/antiox12071349 · Cited by 23
Zhang, H., Wang, X., Qu, M., Li, Z., Yin, X., Tang, L., Liu, X., & Sun, Y. (2023) · Autophagy · doi:10.1080/15548627.2023.2233847 · Cited by 23
“To date, 18 human HDACs have been recognized that are grouped into four classes based on their sequence homology to yeast HDACs, class I (HDAC1HDAC3, and HDAC8), class II (HDAC4-HDAC7, HDAC9, and HDAC10), class Ш (SIRT1 through SIRT7), class IV (HDAC11) [35,43].”
BackgroundA Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors
Drakontaeidi, A., & Pontiki, E. A. (2023) · Pharmaceuticals · doi:10.3390/ph16121639 · Cited by 30
HDAC inhibitors cause site-specific chromatin remodeling at PU.1-bound enhancers in K562 cells
Frank, C. L., Manandhar, D., Gordân, R., & Crawford, G. E. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0065-5 · Cited by 31
Chidamide alleviates TGF-β-induced epithelial–mesenchymal transition in lung cancer cell lines
Lin, S., Wang, B., Lin, C., Chien, P., Wu, Y., Ko, J., & Chen, J. J. W. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4005-z · Cited by 24
Yang, D., Xie, J., Liu, K., Peng, Z., Guo, J., Yu, S., Wang, G., & Gong, S. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.09.036 · Cited by 23
Uba, A. İ., Weako, J., Keskin, Ö., Gürsoy, A., & Yelekçi, K. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1615989 · Cited by 24
“…of cancers (Lehmann, et al., 2014; Park et al., 2011; Yan et al., 2013) including neuroblastoma (Chakrabarti et al., 2016; Rettig et al., 2015), neurodegenerative disorders, metabolic dysregulation and autoimmune and inflammatory diseases (Falkenberg & Johnstone, 2014; Tang, Yan, & Zhuang, 2013).”
BackgroundDiscovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor
Soumyanarayanan, U., Ramanujulu, P. M., Mustafa, N. B., Haider, S. M., Nee, A. H. F., Tong, J. X., Tan, K. S. W., Chng, W. J., & Dymock, B. W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111755 · Cited by 24
Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
Goutas, D., Theocharis, S. E., & Tsourouflis, G. S. (2021) · Diagnostics · doi:10.3390/diagnostics11081346 · Cited by 23
“Since then, several major classes of HDACis have been developed, including short-chain fatty-acid derived, cyclic tetra/depsipeptides, hydroxamic acid-based and amino-benzamide-based inhibitors [9], as well as a newly discovered hydrazide-based HDACi [10,11].”
BackgroundSIRT2 deficiency prevents age-related bone loss in rats by inhibiting osteoclastogenesis
Jing, Y., Zhou, Y., Zhou, F., Wang, X., Tao, B., Sun, L., Liu, J., & Zhao, H. (2019) · Cellular and Molecular Biology · doi:10.14715/cmb/2019.65.7.12 · Cited by 22
“In recent years, members of HDACs have been investigated as molecular targets for various disorders (15, 25, 26).”
BackgroundHDAC8 as a target in drug discovery: Function, structure and design
Zhao, Q., Liu, H., Peng, J., Niu, H., Liu, J., Xue, H., Liu, W., Liu, X., Hao, H., Zhang, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116972 · Cited by 25
Mechanism for neurotropic action of vorinostat, a pan histone deacetylase inhibitor
Shukla, S., Shariat‐Madar, Z., Walker, L., & Tekwani, B. L. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.09.003 · Cited by 22
Luque-Martin, R., den Bossche, J. V., Furze, R. C., Neele, A. E., van der Velden, S., Gijbels, M. J., van Roomen, C. P. A. A., Bernard, S. G., de Jonge, W. J., Rioja, I., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01242 · Cited by 24
Yang, T., Wang, P., Yin, X., Zhang, J., Huo, M., Gao, J., Li, G. L., Teng, X., Yu, H., Huang, W., et al. (2020) · Theranostics · doi:10.7150/thno.48314 · Cited by 24
“Studies have revealed that HDACs are highly expressed in a variety of tumors and can play a critical role in cancer progression by reversing the transformed phenotype, inhibiting cell proliferation, triggering cell cycle arrest, and inducing apoptosis [2].”
BackgroundUllmann, T., Luckhardt, S., Wolf, M., Parnham, M. J., & Resch, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063022 · Cited by 25
Mensah, A. A., Spriano, F., Sartori, G., Priebe, V., Cascione, L., Gaudio, E., Tarantelli, C., Civanelli, E., Aresu, L., Rinaldi, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003566 · Cited by 24
Epigenetic Regulation of Circadian Clocks and Its Involvement in Drug Addiction
Saad, L., Zwiller, J., Kalsbeek, A., & Anglard, P. (2021) · Genes · doi:10.3390/genes12081263 · Cited by 25
“HDMs serve as important targets for several systems involved in addiction [14,15] and circadian rhythms [16].”
BackgroundThe Role of Histone Acetylation in Mesenchymal Stem Cell Differentiation
Jang, S., Hwang, J., & Jeong, H. (2022) · Chonnam Medical Journal · doi:10.4068/cmj.2022.58.1.6 · Cited by 22
“Identify the HDAC component molecules as well as understanding their activity is essential in for their emergence as a potential therapeutic strategy for treatment of disease, including cancer, immune disorders, and heart disease.(8,13,14) Histone demethylases play regulatory roles in transcription for demethylation o…”
BackgroundMo, H., Zhang, R., Chen, Y., Li, S., Wang, Y., Zou, W., Lin, Q., Zhao, D., Du, Y., Zhang, K., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114705 · Cited by 22
Li, Z., Duan, P., Qiu, R., Fang, L., Fang, P., & Xiao, S. (2023) · Journal of Virology · doi:10.1128/jvi.00375-23 · Cited by 24
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 27
“Histone Deacetylase (HDAC) Inhibitors HDAC inhibitors (HDACi) are known to have potent antitumor effects, inducing cell death, cell cycle arrest, senescence and autophagy, amongst other effects [247].”
HDAC activity is dispensable for repression of cell-cycle genes by DREAM and E2F:RB complexes
Barrett, A. K., Shingare, M. R., Rechtsteiner, A., Rodriguez, K. M., Le, Q. N., Wijeratne, T. U., Mitchell, C. E., Membreño, M. W., Rubin, S. M., & Müller, G. A. (2024) · Nature Communications · doi:10.1038/s41467-024-48724-0 · Cited by 27
“See Supplementary Data 2 for the list of antibodies used for Western blotting.”
InfluentialHDAC3 in action: Expanding roles in inflammation and inflammatory diseases
He, R., He, Z., Zhang, T., Liu, B., Gao, M., Li, N., & Geng, Q. (2024) · Cell Proliferation · doi:10.1111/cpr.13731 · Cited by 27
Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isoform!
Guadagni, A., Barone, S., Alfano, A. I., Pelliccia, S., Bello, I., Panza, E., Summa, V., & Brindisi, M. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116884 · Cited by 28
Liu, D., Andrade, S. P., Castro, P. R., Treacy, J., Ashworth, J., & SLEVIN, M. A. (2016) · Scientific Reports · doi:10.1038/srep34649 · Cited by 27
Reddy, D. R., Ballante, F., Zhou, N., & Marshall, G. R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.032 · Cited by 23
Wang, H., Kohashi, K., Yoshizumi, T., Okumura, Y., Tanaka, Y., Shimokawa, M., Iwasaki, T., Aishima, S., Maehara, Y., & Oda, Y. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.03.007 · Cited by 24
Gabr, M. T., El‐Gohary, N. S., El‐Bendary, E. R., El‐Kerdawy, M. M., & Ni, N. (2017) · Europe PMC (PubMed Central) · doi:10.17179/excli2017-208 · Cited by 22
“Abnormalities in the deacetylation function of histones were recognized in various human tumors (Falkenberg and Johnstone, 2014).”
Transcriptional and epigenetic regulation of ncx1 and ncx3 in the brain
Formisano, L., Guida, N., Mascolo, L., Serani, A., Laudati, G., Pizzorusso, V., & Annunziato, L. (2020) · Cell Calcium · doi:10.1016/j.ceca.2020.102194 · Cited by 25
Ningappa, M., Ashokkumar, C., Higgs, B. W., Sun, Q., Jaffe, R., Mazariegos, G. V., Li, D. Y., Weeks, D. E., Subramaniam, S., Ferrell, R. E., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13509 · Cited by 23
Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat
Rivera, S., Leteur, C., Mégnin-Chanet, F., Law, F., Martins, I., Kloos, I., Depil, S., Modjtahedi, N., Perfettini, J., Hennequin, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14813 · Cited by 22
Progress Towards a Public Chemogenomic Set for Protein Kinases and a Call for ContributionsPreprint
Drewry, D. H., Wells, C. I., Andrews, D. M., Angell, R. M., Al‐Ali, H., Axtman, A. D., Capuzzi, S. J., Elkins, J. M., Ettmayer, P., Frederiksen, M. U., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/104711 · Cited by 23
Zhao, C., Zhang, J., Zhou, H., Setroikromo, R., Poelarends, G. J., & Dekker, F. J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00836 · Cited by 21
Rubio‐Ruíz, B., Pérez‐López, A. M., Sebastián, V., & Unciti‐Broceta, A. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116217 · Cited by 21
Xiao, S.-H., Guo, S., Han, J., Sun, Y., Wang, M., Chen, Y., Fang, X., Yang, F., Mu, Y., Zhang, L., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab989 · Cited by 16
“Many histone modification enzymes have already had potent and selective inhibitors with welldemonstrated binding mode and distinct mechanism of action, including EZH2 (19), Dot1L (20), p300 (21), PRMTs (22,23), SMYDs (24,25), LSD1 (26), KAT6A/B (27), KDM6B (28) and HDACs (29).”
Yang, L., Chen, S., Xia, J., Zhou, Y., Peng, L., Fan, H., Han, Y., Duan, L., Cheng, G., Yang, H., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00814-6 · Cited by 24
“Through interacting with histones and non-histones, they exert various effects on chromatin remodeling, transcriptional regulation and protein stability [4], with important contributions to physiological or pathological processes.”
BackgroundOmidkhah, N., Hadizadeh, F., Abnous, K., & Ghodsi, R. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133599 · Cited by 21
Deacetylation of K481 and K484 on Penaeid Shrimp Hemocyanin Is Critical for Antibacterial Activity
Nie, J., Aweya, J. J., Yu, Z., Zhou, H., Wang, F., Yao, D., Zheng, Z., Li, S., Ma, H., & Zhang, Y. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200078 · Cited by 21
Zhou, J., Wu, X., Zhang, H., Wang, X., Yuan, Y., Zhang, S., Jiang, Z., & Wang, T. (2022) · The Breast · doi:10.1016/j.breast.2022.10.018 · Cited by 23
“Tucidinostat, a histone deacetylase (HDAC) inhibitor, induces cell cycle arrest, differentiation, and death in cancer cells by modifying the status of acetylation on histone and non-histone proteins and changes the tumor microenvironment to exert anti-tumor effects [14].”
BackgroundPeng, X., Yu, Z., Surineni, G., Deng, B., Zhang, M., Li, C., Sun, Z., Pan, W., Liu, Y., Liu, S., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2201408 · Cited by 23
“R Particularly, HDACs play a key role in a variety of cellular processes such as transcription, cell cycle, and cellular metabolism 2 .”
RetractedMolecular control of CD4+ T cell lineage plasticity and integrity
Ellmeier, W. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.03.050 · Cited by 22
Cincinelli, R., Zwick, V., Musso, L., Zuco, V., Cesare, M. D., Zunino, F., Simões‐Pires, C. A., Nurisso, A., Giannini, G., Cuendet, M., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.001 · Cited by 21
Anticancer RuII and RhIII Piano‐Stool Complexes that are Histone Deacetylase Inhibitors
Cross, J. M., Blower, T. R., Gallagher, N., Gill, J. H., Rockley, K. L., & Walton, J. W. (2016) · ChemPlusChem · doi:10.1002/cplu.201600413 · Cited by 22
Molecular structures guide the engineering of chromatin
Tekel, S. J., & Haynes, K. A. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx531 · Cited by 23
“Bromodomain inhibitors such as JQ1 (120) and I-BET (121) have been identified in high throughput screens to identify small compounds that fit the histone recognition pocket of BRD2 (1- 473), BRD3 (1-434) and BRD4 (1-477) (121).”
BackgroundInfluentialRyu, H.-W., Shin, D.-H., Lee, D. H., Won, H.-R., & Kwon, S. H. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx121 · Cited by 20
Pisarello, M. J. L., Masyuk, T. V., Gradilone, S. A., Masyuk, A. I., Ding, J., Lee, P. Y., & LaRusso, N. F. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.12.016 · Cited by 21
Zhang, Y., Zheng, X., Tan, H., Lu, Y., Tao, D., Liu, Y., & Ma, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0462-8 · Cited by 21
A KAT6A variant in a family with autosomal dominantly inherited microcephaly and developmental delay
Trinh, J., Hüning, I., Yüksel, Z., Baalmann, N., Imhoff, S., Klein, C., Rolfs, A., Gillessen‐Kaesbach, G., & Lohmann, K. (2018) · Journal of Human Genetics · doi:10.1038/s10038-018-0469-0 · Cited by 21
Targeting the Post-translational Proteome with Intrabodies
Cattaneo, A., & Chirichella, M. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.11.009 · Cited by 21
Combined Ligand and Fragment‐based Drug Design of Selective Histone Deacetylase – 6 Inhibitors
Ružić, D., Petković, M., Agbaba, D. D., Ganesan, A., & Nikolic, K. M. (2019) · Molecular Informatics · doi:10.1002/minf.201800083 · Cited by 21
Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)
Tomaselli, D., Mautone, N., Mai, A., & Rotili, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112750 · Cited by 21
Progression-seeking bias and rational optimism in research and development
Lendrem, D. W., Lendrem, C., Peck, R., Senn, S. J., Day, S. J., & Isaacs, J. D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4320-c1 · Cited by 22
Subramanian, K., Hutt, D. M., Scott, S. M., Gupta, V. R., Mao, S., & Balch, W. E. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010524 · Cited by 22
“HDACs play regulatory roles in many biological processes, and recently emerged as promising therapeutic targets to correct the defects associated with several protein misfolding diseases (112).”
BackgroundHirata, Y., Sasaki, T., Kanki, H., Choong, C.-J., Nishiyama, K., Kubo, G., Hotei, A., Taniguchi, M., Mochizuki, H., & Uesato, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19664-9 · Cited by 20
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.